

Emcure Pharmaceuticals expands manufacturing footprint in Mehsana, Gujarat

- *Inaugurates new injectables facility that will start supplying to the markets*
- *Inaugurated by Shri. Rushikeshbhai Patel, Honourable Minister of Health and Family Welfare, Government of Gujarat*
- *Company has made significant investments in manufacturing operations in Gujarat*

December 30, 2023, Mehsana: Emcure Pharmaceuticals, one of India's leading pharma companies, inaugurated its recently commissioned facility at Mehsana in Gujarat. The inauguration was done by Shri. Rushikeshbhai Patel, Honourable Minister of Health and Family Welfare, Gujarat. The new plant manufactures injectables for sale in India as well as for export to global markets.

Emcure's manufacturing operations have been established for decades, and are spread across 13 sites in India. The company currently has an oral formulations manufacturing line at Mehsana and the new unit commissioned in August, 2023 is now ready for commercial supplies to domestic and international markets.

With dedicated manufacturing facilities for different platforms and packaging formats, Emcure's manufacturing facilities across the country are capable of producing pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs. With approvals and accreditations from various regulatory authorities such as EDQM, Health Canada, USFDA, ANVISA Brazil, and more, the company ensures that it remains in compliance with the relevant regulations and is able to supply products in regulated and other markets.

Shri Rushikeshbhai Patel, Honourable Minister of Health and Family Welfare, Government of Gujarat praised Emcure's commitment towards providing accessible and affordable healthcare and said, *"The inauguration of the new manufacturing plant by Emcure Pharmaceuticals in Mehsana, Gujarat marks a pivotal moment in India's pursuit of providing quality pharmaceutical products for both the Indian and international markets. This facility, equipped with the latest technology and adherence to quality control measures, underscores their dedication to ensuring that each product meets and exceeds global pharmaceutical benchmarks."*

Emcure's new manufacturing plant will aim at creating additional job opportunities in the local market.

Speaking on the occasion, **Mr. Satish Mehta, Founder and CEO, Emcure Pharmaceuticals** said, *"The new Mehsana facility represents our continued investment in Gujarat, aligning with our vision to bring solutions to address the unmet medical needs and improve patient outcomes globally. We believe that the new capacity addition will help meet the growing demand for our differentiated product portfolio across markets."*

Disclaimer

"Emcure Pharmaceuticals Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offering of its equity shares and has filed a draft red herring prospectus dated December 16, 2023 ("DRHP") with the Securities and Exchange Board of India ("SEBI"). The DRHP is available on the websites of the Company at [Emcure.com](https://emcure.com), SEBI at www.sebi.gov.in, the book running lead managers, Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and JP Morgan India Private Limited at <https://investmentbank.kotak.com>, www.axiscapital.co.in, www.jefferies.com and www.jpmpil.com, respectively, and the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details refer to the Red Herring Prospectus, including the section titled "Risk Factors" of the Red Herring Prospectus when available. Potential investors should not rely on the DRHP for making any investment decision."

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is one of India's leading pharmaceutical players headquartered in Pune with global footprint and is driven by technology and innovation. Established in 1981, the firm was founded by Mr. Satish Mehta, and is ranked as the 13th largest pharma company in India in terms of domestic sales (AIOCD-AWACS MAT Sep 23).

To know more about Emcure, please visit: <https://www.emcure.com/>

Follow us on LinkedIn: <https://www.linkedin.com/company/emcure-pharmaceuticals-limited/>